12th May 2022 | Pharma Updates
Bayer reintroduces antifungal Canesten in India
Bayer’s consumer health division has announced a new and improved range of Canesten, an antifungal treatment product in India that aid in the prevention and treatment of skin infections.
Alembic Pharma receives final USFDA approval
Alembic has received final approval from the USFDA for its generic version of Arformoterol Tartrate inhalation solution for the longterm treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease.
The late-stage trial of two lung cancer drugs conducted by Roche fails
A Roche study combining tiragolumab and tecentriq to treat a kind of lung cancer failed in a late-stage trial, the Swiss pharmaceuticals company announced on Wednesday.
Neuberg Diagnostic opens processing lab in Gurugram
Neuberg Diagnostics announced its Haryana expansion by opening its own processing centre in Gurugram. In addition, to celebrate their progress, they are opening 10 express diagnostics laboratories and 100 touchpoints across Haryana.
PAG invests Rs 2,000 crore for controlling interestin Optimus Drugs
PAG, an Asia-Pacific investment firm, is acquiring a majority share in Hyderabad based Optimus Drugs. As per sources, PAG and consortium partners CX Partners and Samara Capital have agreed to invest Rs 2,000 crore in Optimus medicines.
Biological E requests EUA for Corbevax as a booster in adults
Biological E has applied to India’s drug authority for emergency use authorization for its Covid-19 vaccine Corbevax as a booster dosage for people who have had two doses of either Covishield or Covaxin.
Delhi pharma firm acquired intellectual property of B'luru scientists
Delhi-based pharma firm has been granted the intellectual property of a game-changing therapeutic molecule for Alzheimer’s disease produced by scientists at the JNCASR in Bengaluru more than a year ago.